Private Industry Embraces Promising Type 1 Therapy

To take a promising drug to market, it costs on average $500 million.  Academic research institutions such as UCSF excel in conducting basic research and early stage human clinical trials, however, for cost reasons it is important that promising therapies are picked up by private industry.

Last month, thanks to the efforts of the Juvenile Diabetes Research Foundation (JDRF), two pharmaceutical companies entered into global alliances to develop and commercialize Anti-CD3 drug therapies to treat and potentially to prevent type 1diabetes:  Eli Lilly and MacroGenics will be developing teplizumab, and GlaxoSmithKline and Tolerx will be developing otelixizumab.  For the early pioneers of Anti-CD3 - Dr. Jeffrey Bluestone at UCSF and Dr. Kevan Herold at Yale - this is exciting news.